Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


28.11.2022

2 AJR Am J Roentgenol
2 Aliment Pharmacol Ther
1 Am J Gastroenterol
5 BMC Gastroenterol
2 Clin Gastroenterol Hepatol
13 Dis Colon Rectum
1 Gastroenterol Hepatol
1 Gastroenterology
4 Inflamm Bowel Dis
9 J Crohns Colitis


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SHENOY-BHANGLE AS, Gee MS
    CT Versus MR Enterography: Counterpoint-MR Enterography Is the Primary Imaging Modality for Assessing Activity and Therapeutic Response in Pediatric and Adult Crohn Disease.
    AJR Am J Roentgenol. 2022 Nov 23. doi: 10.2214/AJR.22.28778.
    PubMed        

  2. THOMAS SP, Jaffe TA
    CT Versus MR Enterography: Point-CT Enterography Remains Essential to Imaging Patients With Inflammatory Bowel Disease in the Acute Setting.
    AJR Am J Roentgenol. 2022 Nov 23. doi: 10.2214/AJR.22.28716.
    PubMed        


    Aliment Pharmacol Ther

  3. BUISSON A, Nachury M, Guilmoteau T, Altwegg R, et al
    Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Aliment Pharmacol Ther. 2022 Nov 19. doi: 10.1111/apt.17305.
    PubMed         Abstract available

  4. ZISMAN-ILANI Y, Thompson KD, Siegel LS, Mackenzie T, et al
    Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
    Aliment Pharmacol Ther. 2022 Nov 14. doi: 10.1111/apt.17286.
    PubMed         Abstract available


    Am J Gastroenterol

  5. VARMA A, Weinstein J, Seabury J, Rosero S, et al
    Patient-Reported Impact of Symptoms in Crohn's Disease.
    Am J Gastroenterol. 2022 Nov 15. doi: 10.14309/ajg.0000000000001954.
    PubMed         Abstract available


    BMC Gastroenterol

  6. FENG W, Liu Y, Zhu L, Xu L, et al
    Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study.
    BMC Gastroenterol. 2022;22:485.
    PubMed         Abstract available

  7. AL QTEISHAT A, Kirov K, Bokov D
    The profile of the key pro-inflammatory cytokines in the serum of patients with CD and their association with the disease severity and activity.
    BMC Gastroenterol. 2022;22:477.
    PubMed         Abstract available

  8. HUNTER T, Naegeli AN, Nguyen C, Shan M, et al
    Medication use among patients with Crohn's disease or ulcerative colitis before and after the initiation of advanced therapy.
    BMC Gastroenterol. 2022;22:474.
    PubMed         Abstract available

  9. LIU J, Tao Y, Haikun W, Lanfang Y, et al
    Triclosan exposure induced disturbance of gut microbiota and exaggerated experimental colitis in mice.
    BMC Gastroenterol. 2022;22:469.
    PubMed         Abstract available

  10. ZENG S, Lin Y, Guo J, Chen X, et al
    Differential diagnosis of Crohn's disease and intestinal tuberculosis: development and assessment of a nomogram prediction model.
    BMC Gastroenterol. 2022;22:461.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  11. SINGH S, Kim J, Luo J, Paul P, et al
    Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Clin Gastroenterol Hepatol. 2022 Nov 4:S1542-3565(22)01018.
    PubMed         Abstract available

  12. BUISSON A, Nachury M, Fumery M
    Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Nov 16:S1542-3565(22)01084.
    PubMed        


    Dis Colon Rectum

  13. ROUSSEL BN, Shah SA
    Diagnosis and Management of Functional Pouch Disorders: A Systematic Review.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  14. HEMBREE AE, Scherl E
    Diagnosis and Management of Cuffitis: A Systematic Review.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  15. LEE KE, Shen B
    Endoscopic Therapy for Pouch Leaks and Strictures: A Systematic Review.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  16. CHURCH J
    Nuances of Ileal Pouch-Anal Anastomosis in Familial Adenomatous Polyposis.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  17. LYNCH AC
    Robotic Surgery for the Ileal Pouch.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  18. AKIYAMA S, Dyer EC, Rubin DT
    Diagnostic and Management Considerations for the IPAA With Crohn's Disease-Like Features.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  19. CHIS RS, Silverberg MS
    Measurement of Disease Activity of Pouchitis.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  20. ANGISTRIOTIS A, Shen B, Kiran RP
    Construction of and Conversion to Continent Ileostomy: A Systematic Review.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  21. TOME J, Raffals LE, Pardi DS
    Management of Acute and Chronic Pouchitis.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  22. PARIGI TL, Nardone OM, Iacucci M
    Image-Enhanced Endoscopy Surveillance of Colon and Pouch Dysplasia in IBD.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  23. SHAFFER SR, Bernstein CN
    Controversies in Crohn's Disease Before and After Pouch Surgery.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  24. BALLENTINE S, Lee H, Liu X
    Histopathology of Pouch and Para-Pouch Inflammatory and Neoplastic Disorders.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available

  25. SUGITA A, Koganei K, Tatsumi K
    Management of Pouch Neoplasia.
    Dis Colon Rectum. 2022;65.
    PubMed         Abstract available


    Gastroenterol Hepatol

  26. VICENS DG, Belinchon MR, Mateu PN, Elena Pejenaute Labari M, et al
    Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) survey on the management of patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022 Nov 16:S0210-5705(22)00269.
    PubMed         Abstract available


    Gastroenterology

  27. LI Y, Pengbo S, Feng Y
    A new evaluation method for remission of ulcerative colitis.
    Gastroenterology. 2022 Nov 22:S0016-5085(22)01345.
    PubMed        


    Inflamm Bowel Dis

  28. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease.
    Inflamm Bowel Dis. 2022 Nov 25:izac231. doi: 10.1093.
    PubMed         Abstract available

  29. CHEN K, Chen J, Smith E, Mathani P, et al
    Serum Ustekinumab Concentrations Are Associated With Improved Outcomes With the Magnetic Resonance Index of Activity for Crohn's Disease.
    Inflamm Bowel Dis. 2022 Nov 24:izac236. doi: 10.1093.
    PubMed        

  30. COLMAN RJ, Samuels A, Mizuno T, Punt N, et al
    Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2022 Nov 22:izac237. doi: 10.1093.
    PubMed        

  31. YOGEV D, Verstockt B, Dignass A, Focht G, et al
    The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's Disease.
    Inflamm Bowel Dis. 2022 Nov 9:izac235. doi: 10.1093.
    PubMed        


    J Crohns Colitis

  32. EL-ZIMAITY H, Shaffer SR, Riddell RH, Pai RK, et al
    Beyond Neutrophils for predicting relapse and remission in ulcerative colitis.
    J Crohns Colitis. 2022 Nov 25:jjac178. doi: 10.1093.
    PubMed         Abstract available

  33. KONTOLA K, Oksanen P, Huhtala H, Jussila A, et al
    Increasing incidence of inflammatory bowel disease with greatest change among the elderly: a nationwide study in Finland, 2000-2020.
    J Crohns Colitis. 2022 Nov 24:jjac177. doi: 10.1093.
    PubMed         Abstract available

  34. KUMAR L, Doherty G
    The Tortoise (Endoscopy-Driven Treatment) and the Hare (Prophylactic Treatment): Who Wins the Race to Beat Post-Operative Recurrence of Crohn's Disease?
    J Crohns Colitis. 2022 Nov 17:jjac165. doi: 10.1093.
    PubMed        

  35. VAN DER DOES DE WILLEBOIS EML, Duijvestein M, Wasmann KA, D'Haens GRAM, et al
    Endoscopic Recurrence or Anastomotic Wound Healing Phenomenon after Ileocolic Resection for Crohn's Disease: The Challenges of Accurate Endoscopic Scoring.
    J Crohns Colitis. 2022 Nov 16:jjac175. doi: 10.1093.
    PubMed         Abstract available

  36. FIOCCHI C, Iliopoulos D
    Numbers Do Not Lie: The Dire Need for New Directions in IBD.
    J Crohns Colitis. 2022;16:1649-1650.
    PubMed        

  37. KRUIS W, Siegmund B, Lesniakowski K, Simanenkov V, et al
    Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
    J Crohns Colitis. 2022;16:1714-1724.
    PubMed         Abstract available

  38. ZUO L, Li J, Zhang X, Geng Z, et al
    Aberrant Mesenteric Adipose Extracellular Matrix Remodelling is Involved in Adipocyte Dysfunction in Crohn's Disease: The Role of TLR-4-mediated Macrophages.
    J Crohns Colitis. 2022;16:1762-1776.
    PubMed         Abstract available

  39. BACHOUR SP, Shah RS, Rieder F, Qazi T, et al
    Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence.
    J Crohns Colitis. 2022;16:1696-1705.
    PubMed         Abstract available

  40. BERERA S, Ioannou SC, Morillo D, Mantero AMA, et al
    Combining Pentoxifylline With Vedolizumab for Crohn's Disease: Results of a Randomised, Placebo-controlled Pilot Study.
    J Crohns Colitis. 2022;16:1687-1695.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: